Table 1.
General characteristics of the patients included in the study (n = 58). BMI: Body Mass Index. IgE: Inmunoglobulin E. FEV1: forced expiratory volume in 1 s. FVC: Forced Vital Capacity. ACT: Asthma Control Test. ACQ: Asthma Control Questionnaire. VAS: Visual Analogue Scale. SNOT-22: 22-item Sino-Nasal Outcome Test. AQLQ: Asthma Quality of Life Questionnaire. ENT: Ear, Nose and Throat.
| Baseline Characteristics | Value/Mean ± Standard Deviation |
|---|---|
| Mean age (years) | 55 ± 14 |
| BMI (Kg/m2) | 27 ± 8 |
| Sex | 64% women, 36% men |
| Eosinophils, cel/μL | 786 ± 504 |
| IgE (UI/mL) | 361 ± 807 |
| Atopy/allergy | 17 patients |
| FEV1 (Liters and %) | 2.45 ± 0.8 (84 ± 18%) |
| FEV1/FVC (%) | 69.5 ± 10 (%) |
| FVC (liters and %) | 3.47 ± 1.01 (97 ± 16%) |
| ACT // ACQ// VAS | 15 ± 2 // 3 ± 1 // 7.5 ± 1 |
| SNOT-22 | 55 ± 17 |
| VAS: | |
| Obstruction | 8 ± 1 |
| Runny nose | 7.8 ± 1 |
| Anosmia | 7.6 ± 1 |
| Facial pressure | 7.8 ± 1 |
| Mini-AQLQ | 2.4 ± 0.4 |
| Number emergency visits / year | 2.62 ± 2.7 |
| Number of hospital admissions/year | 0.84 ± 2 |
| Days of hospital admission | 3 ± 8 |
| Global exacerbations | 5.6 ± 5 |
| Oral glucocorticoid cycles | 3.16 ± 3 |
| Time of treatment (months) | 14.4 ± 8 |
| Previous ENT surgery (one or more) | Total: 55% (32) One: 47% (15) Two: 31% (10) Three or more: 22% (7) |